Beyond-use dating is one of the most misunderstood parts of USP 797, mostly because pharmacists conflate it with an expiration date. It isn’t one. A beyond-use date (BUD) is the point after which a compounded sterile preparation should not be used, based on evidence (or the absence of evidence) about how long that specific preparation remains sterile and stable under specific storage conditions. Getting the framework right matters for both patient safety and inspection readiness.
BUD vs. expiration date — not the same thing
An expiration date is manufacturer-established, based on formal stability testing of a specific commercial product. A beyond-use date is compounder-established, based on the compounding process, the ingredients used, and — critically — the level of sterility assurance built into that specific preparation. Two pharmacies compounding what looks like the same product can land on very different BUDs if their processes, testing, and storage conditions differ.
The category framework: default dating without testing
USP 797 organizes compounded sterile preparations (CSPs) into categories that determine the default BUD when a pharmacy hasn’t performed (or doesn’t have access to) sterility testing to support a longer date. Broadly:
- Category 1 preparations get the shortest default BUDs — compounded in unclassified segregated compounding areas, intended for more immediate use.
- Category 2 preparations, compounded under more controlled conditions (classified environments, more robust environmental monitoring), get longer default BUDs without additional testing.
- Category 3 preparations can receive the longest BUDs, but only when supported by sterility testing, endotoxin testing, and stability data specific to that preparation.
The exact default time windows and the specific testing requirements to unlock longer dating are detailed in the USP 797 chapter itself and are periodically revised — treat any specific hour or day figure you’ve memorized as something to re-verify rather than something to rely on indefinitely, since revision cycles do change these numbers.
Storage condition changes everything
The same preparation can carry different BUDs depending on whether it’s stored at controlled room temperature, refrigerated, or frozen — refrigeration and freezing generally support longer dating because they slow microbial growth and degradation. This is why BUD isn’t a single number per drug; it’s a function of category, storage condition, and container closure system together.
State adoption isn’t automatic or uniform
USP 797 is a compendial standard, but it only carries legal force in a state once that state’s board of pharmacy formally adopts it — and the timing and specifics of adoption vary. Some states adopt USP chapters by reference shortly after each revision cycle; others lag by months or years, or adopt with modifications specific to that state. A pharmacy operating across multiple states can legitimately be subject to different versions or interpretations of the standard depending on where it’s compounding and dispensing.
This is the same adoption-lag issue we cover in more detail in our USP 800 compliance by state breakdown — the two chapters travel together in most state adoption processes, so it’s worth checking both when you’re mapping requirements for a new state.
Where BUD errors typically originate
Applying a BUD from one storage condition to another — moving a preparation from refrigerated to room-temperature storage without adjusting the BUD downward.
Assuming testing done on one formulation covers a similar one — sterility and stability data are specific to the tested preparation; a similar drug or concentration doesn’t automatically inherit the same dating.
Missing a state-specific modification — a handful of states have adopted USP 797 with additional restrictions beyond the base compendial standard.
Confusing 503A and 503B dating frameworks — outsourcing facilities operating under 503B are subject to different regulatory expectations than 503A pharmacies, which affects how BUD and stability data are documented. Our 503A vs 503B differences piece breaks that distinction down further.
Building BUD compliance into your workflow
A working sterile compounding program typically documents, for every preparation type: the category assignment and rationale, the storage condition assumed, whether sterility/stability testing supports an extended date, and the source of that testing (in-house validated data vs. compendial default). This documentation is usually exactly what a board inspector asks to see first.
If your role includes ongoing sterile compounding training, our sterile compounding training requirements post covers how BUD competency typically fits into initial and periodic staff training expectations. For personnel-level certification questions, the USP 797 glossary entry is a quick reference.
Beyond-use dating requirements and state adoption timelines change with each USP revision cycle, so confirm the current chapter language and your state board’s adoption status before finalizing dating policies at your facility.
RxByState tracks USP 797 and USP 800 adoption status, along with related compounding requirements, across all 50 states and DC. Start your free trial →